NEWPORT BEACH, Calif., Oct. 07, 2022 (GLOBE NEWSWIRE) — CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced it will exhibit its TRANBERG
“We’re excited to introduce our office-based TRANBERG focal laser ablation system to the urologists and providers at the Unio Health Partners Summit,” said Michael Magnani, president of CLS Americas. “Unio provides best-in-class clinical programs and ancillary services to its affiliates. It’s a great opportunity for us to partner with them for the summit.”
TRANBERG
The TRANBERG
About CLS and the TRANBERG®Product Portfolio
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including ThermoguideTM Workstation and sterile disposables, for minimally invasive laser ablation of soft tissue, cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. CLS aims at expanding the current approvals to also include treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal treatment effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company’s website for the US market: www.clinicallaser.com/en.
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow